Patrick Hilley

Loading... 2 0 20 0 false
Credit Name
Patrick Hilley
Full Name
Hilley, Patrick
 
 
Loading... 3 0 20 0 false

Publications

Results 1-7 of 7 (Search time: 0.005 seconds).

Publication YearTitleAuthor(s)
112-Jan-2024Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?Hilley, Patrick ; Wong, Darren; Ma, Ronald ; Peterson, Adam; De Cruz, Peter P 
2Dec-2023Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis.Hilley, Patrick ; Con, Danny; Choy, Matthew C ; Srinivasan, Ashish ; De Cruz, Peter P 
3Aug-2023Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis.Eqbal, Ali; Hilley, Patrick ; Choy, Matthew C ; Srinivasan, Ashish ; De Cruz, Peter P 
430-Mar-2022Combination Tofacitinib and Calcineurin Inhibitor in the Management of Treatment-Refractory Ulcerative Colitis May Be Effective, But Is It Necessary?Peterson, Adam R; Hilley, Patrick ; De Cruz, Peter P 
52022Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.Gilmore, Robert B ; Hilley, Patrick ; Srinivasan, Ashish ; Choy, Matthew C ; De Cruz, Peter P 
619-Aug-2021Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.Hilley, Patrick ; Gilmore, Robert B ; Srinivasan, Ashish ; Choy, Matthew C ; De Cruz, Peter P 
7Jun-2021Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.Gilmore, Robert B ; Hilley, Patrick ; Srinivasan, Ashish ; Choy, Matthew C ; Grace, Josephine A ; De Cruz, Peter P